M. Rudoltz

发表

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

Martin C. Müller, J. Radich, R. Larson, 2010, Blood.

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

J. Radich, M. Baccarani, B. Druker, 2009 .

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

J. Radich, R. Larson, B. Druker, 2010, Leukemia.

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

R. Larson, H. Kantarjian, B. Druker, 2009, Cancer.

Multiple causes of cerebrovascular events in children with tumors of the parasellar region

J. Langston, W. Regine, R. Sanford, 1998, Journal of Neuro-Oncology.

Second malignant neoplasia in patients with T1 glottic cancer treated with radiation

W. Regine, M. Mohiuddin, M. Machtay, 1998, The Laryngoscope.

High‐Dose‐Rate Brachytherapy for Primary Carcinomas of the Oral Cavity and Oropharynx

P. Wludyka, S. Ackerman, M. Rudoltz, 1999, The Laryngoscope.

First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

Hyo Song Kim, F. Janku, J. Cheong, 2022, Investigational New Drugs.

Clinical Trials and Observations

R. A. Larson, Martin C. Müller, J. Radich, 2022 .

Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis

R. Willette, P. Mangrolia, D. Welsch, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Radiotherapy for merkel cell carcinoma of the skin of the head and neck

M. Suntharalingam, S. Stringer, W. Mendenhall, 1995, Head & neck.

In Regard to Brown and Adler.

M. Rudoltz, 2015, International journal of radiation oncology, biology, physics.

Staging of head and neck cancer.

M. Rudoltz, G. Kao, 1995, The New England journal of medicine.

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

A. Tolcher, C. Takimoto, M. Saif, 2005, Clinical Cancer Research.

Ionizing radiation and the cell cycle: A review

R. Muschel, W. Mckenna, G. Kao, 1996 .

Abstract PR01: Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models

Michael D. Kaufman, D. Flynn, S. Wise, 2015 .

The molecular regulation of apoptosis and implications for radiation oncology.

R. Muschel, W. Mckenna, G. Kao, 1997, International journal of radiation biology.

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

J. Radich, R. Larson, B. Druker, 2009, Leukemia.

Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay.

R. Muschel, E. Bernhard, A. Maity, 1996, Oncogene.

Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.

Hyo Song Kim, Tae Won Kim, F. Janku, 2020 .

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Susan Branford, Ricardo Pasquini, Fabrizio Pane, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38)

Martin C. Müller, R. Larson, B. Druker, 2010 .

Repression of LKB1 by miR-17∼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment

Russell G. Jones, M. Minden, N. Johnson, 2019, bioRxiv.

Significance of pretreatment hemoglobin level in patients with T1 glottic cancer.

D. Schultz, W. Regine, M. Mohiuddin, 1999, Radiation oncology investigations.

Prognostic factors for local control and survival in T1 squamous cell carcinoma of the glottis.

M. Mohiuddin, M. Rudoltz, A. Benammar, 1993, International journal of radiation oncology, biology, physics.

Does pathologic node status affect local control in patients with carcinoma of the head and neck treated with radical surgery and postoperative radiotherapy?

M. Mohiuddin, M. Rudoltz, A. Benammar, 1995, International journal of radiation oncology, biology, physics.

Prognostic factors for local control and survival in ti squamous cell carcinoma of the glottis

M. Mohiuddin, M. Rudoltz, A. Benammar, 1992 .

Application of Magnetic Resonance Imaging and Three-Dimensional Treatment Planning in the Treatment of Orbital Lymphoma.

Komanduri Ayyangar, K. Ayyangar, Marc S Rudoltz, 1993, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Effects of Yogurt and Applesauce on the Oral Bioavailability of Nilotinib in Healthy Volunteers

G. Golor, H. Schran, O. Yin, 2011, Journal of clinical pharmacology.

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) *

Martin C. Müller, J. Radich, R. Larson, 2010 .

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

R. Larson, H. Kantarjian, B. Druker, 2010 .